The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human, open label, dose escalating study of B440, an oral cancer vaccine using a WT1-expressing Bifidobacterium, in patients with advanced urothelial cancer.
 
Toshiro Shirakawa
Leadership - Immunorock
Stock and Other Ownership Interests - Immunorock
Research Funding - Immunorock
Patents, Royalties, Other Intellectual Property - Immunorock
 
Junya Furukawa
No Relationships to Disclose
 
Yasumasa Kakei
No Relationships to Disclose
 
Hideto Ueki
No Relationships to Disclose
 
Takuto Hara
No Relationships to Disclose
 
Jun Teishima
No Relationships to Disclose
 
Nobuyuki Hinata
No Relationships to Disclose
 
Hideaki Miyake
No Relationships to Disclose
 
Masato Fujisawa
No Relationships to Disclose